BioCatalystWatch
PHVSWorkspace / PHVS / OverviewCompany library
Price
Market cap
Next catalystExpected Q1 2027deucrictibant XR — CREAATE Part 1 · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

deucrictibant extended-release tablet

Small molecule

Bradykinin B2 receptor

Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

deucrictibant extended-release tablet

Small molecule

Bradykinin B2 receptor

Upcoming / outlook

Other pipelines

History / paused

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

PHVS SEC archive